Thank You

Thanks to everyone who made this year’s Trans-Pacific Health Sciences Dialogue such a great success. We are grateful for the contributions of our attendees, speakers and sponsors that made this such a special event.

See you next year in Boston

Coming Soon: Gallery of Photos from the 2014 Trans-Pacific Health Sciences Dialogue

About the Conference

The Trans-Pacific Health Sciences Dialogue is a C-level meeting for biopharmaceutical industry executives who want to accelerate, explore and develop collaborations and partnerships with their counterparts in the most important Trans-Pacific health care markets including Japan, China, South Korea and North America. This is a must-attend meeting for executives who have, or want to develop, a Trans-Pacific strategy. The event has developed a well-earned reputation as the best place for biopharma companies seeking to forge Trans-Pacific ventures to start exploring their options. Attendees come away with a broad overview and insights they simply will not get in other meetings.

Sponsors

Sponsors_200px

Supporters

Supporters_200px

Who Should Attend

WhoShouldAttend

The Trans-Pacific Health Sciences Dialogue is an invitation-only event for Asian and North American senior biopharmaceutical executives, KOLs and select professional industry advisors, service providers and members of the financial community with a strategic interest in Trans-Pacific collaboration or investment. To request an invitation, please contact Lawrence Joseph.

Industry News from BioCentury

  • VBL prices second IPO attemptVBL Therapeutics Ltd. (NASDAQ:VBLT) raised $40 million through the sale of 6.7 million shares at $6 in an IPO underwritten by Deutsche Bank, JMP and Oppenheimer. This is the company's second attempt at an IPO. Its August IPO was terminated by the underwriters when an investor did not make payments for shares it had agreed to purchase. At that time, the company was offering 5.4 million shares at $12 (see BioCentury Extra, August 8).

    In 1H15, VBL expects to start Phase III testing of its VB-111 gene-based dual anti-angiogenic and vascular disruptive agent (VDA) to treat recurrent glioblastoma.
Read more

Industry News from PharmAsia

  • AZ’s Dapagliflozin Closes On Canagliflozin With India’s SEC NodA new frontier in diabetes care is set to open in India with the Special Expert Committee giving a green light to AstraZeneca’s dapagliflozin, after holding back on safety concerns for a prolonged period.<img src="http://feeds.feedburner.com/~r/_PharmAsiaNews/~4/G1M8pA7e4QY" height="1" width="1" />
Read more

Upcoming Supporter Events

Print

Life Science Future
October 13-14, 2014
Sheraton Downtown Hotel
Philadelphia, PA

Read more